Tilos Therapeutics, Inc. is developing immune-focused antibody therapeutics for the treatment of cancer, fibrosis and autoimmune disease. Tilos’ lead program is focused on antibodies specific for Latency Associated Peptide of TGF beta, based on research from Dr. Howard Weiner’s lab at the Brigham and Women’s Hospital. Tilos was founded in 2016 and is funded by Partners Innovation Fund and Boehringer-Ingelheim Venture Fund.
- Barbara S. Fox, PhD CEO
- Randall Burton, PhD Associate Director Research